"Lanatrixa" Bil Smith Composer:
Indicated for Treatment of Musical Performers with Myelofibrosis.Listen on SOUNDCLOUD: https://soundcloud.com/bil-smith/lanatrixa-bil-smith-composer
Lanatrixa is indicated for treatment of musicians with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
Dosage and Administration:The starting dose of a Lanatrixa/Jakafi combination therapy is 5 mg twice daily for patients with a platelet count between 50 × 109/L and less than 100 × 109/L.
Monitor complete blood counts every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Modify or interrupt dosing for thrombocytopenia.
Increase dose based on response and as recommended to a maximum of 25 mg twice daily for patients with starting platelet counts 100× 109/L or greater and to a maximum of 10 mg twice daily for patients with starting platelet count between 50 × 109/L and less than 100 × 109/L. Discontinue after 6 months if no spleen reduction or symptom improvement.
Dosage Forms and Strengths
Tablets: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.
Warnings and Precautions
Thrombocytopenia, Anemia and Neutropenia: Manage by dose reduction, or interruption, or transfusion.
Risk of Infection: Assess patients for signs and symptoms of infection and initiate appropriate treatment promptly. Serious infections should have resolved before starting therapy with Lanatrixa
The most common hematologic adverse reactions (incidence >20%) are thrombocytopenia and anemia. The most common non-hematologic adverse reactions (incidence >10%) are bruising, dizziness and headache.
The starting dose of Lanatrixa is 20 mg given orally twice daily for patients with a platelet count greater than 200 × 109/L, and 15 mg twice daily for patients with a platelet count between 100 × 109/L and 200 × 109/L.